A negative postmortem blood result did not exclude clonazafone exposure in a published mixed-intoxication case. Targeted testing found this benzodiazepine prodrug in urine, thigh muscle and stomach contents, while femoral blood, heart blood and vitreous humor were reported negative for the parent compound. The case supports specimen-specific investigation, not a universal ranking of matrices or a measured false-negative rate.
The case and the collection interval
Malzacher and colleagues described one 20-year-old man who died after unsuccessful resuscitation. Clonazafone powder and a liquid containing fluoro-etonitazene were recovered from the scene and chemically characterized. Clonazafone is a prodrug that can be converted through an intermediate to clonazepam.
The body was cooled to 5°C six hours after death and remained cooled for 14 hours before autopsy, approximately 20 hours after death. Specimens included femoral blood, heart blood, urine, vitreous humor, stomach contents and thigh muscle. These are the conditions of one investigation, not a controlled comparison across postmortem intervals or decomposition stages.
What was found in each matrix?
Duplicate targeted LC–MS/MS measurements gave semiquantitative clonazafone estimates of 39 ng/mL in urine, 3.0 ng/g in muscle and 76,000 ng/mL in stomach contents. Urine after glucuronidase digestion was reported at 50 ng/mL. Parent clonazafone was not detected in femoral blood, heart blood or vitreous humor; the authors cited a lower quantitation limit of 0.1 ng/mL for the blood method.
A lower quantitation limit is not automatically an independently established detection limit. “Not detected” should retain the particular assay and specimen context. It does not establish that the compound had never been present during life.
Stomach contents totaled approximately 150 mL, corresponding to about 11 mg clonazafone remaining there using the reported estimate. This residual amount is not a reconstructed swallowed dose. It omits any absorbed or eliminated material, and the authors noted that gastric accumulation could have more than one explanation. The findings did not independently prove an administration route.
Why the numerical results require qualification
Certified reference material was unavailable. The investigators used seized clonazafone powder that showed no impurities by GC–MS and infrared analysis and treated it as relatively pure material suitable for semiquantification. Clonazepam-d4 served as the internal standard.
The blood calibration range was 0.1–100 ng/mL. A separate urine calibration covered 50–1,200 ng/mL, and diluted stomach contents were evaluated using that calibration. Notably, the reported urine estimate of 39 ng/mL was below the lowest stated urine calibrator. It should remain an approximate semiquantitative result, rather than being presented as a fully validated quantitative concentration within that urine range.
Ten blank blood samples and two zero samples showed no interfering signals with clonazafone or its internal standard. That selectivity check is useful but is not complete validation in every matrix. The authors explicitly reported that full validation was not performed and that insufficient case material prevented the more accurate standard-addition approach they had considered.
Broad screening and targeted testing did different work
The investigation included routine urine immunoassay screening, instrumental screening and targeted analysis. High-resolution MS detected parent clonazafone in urine and stomach contents; the targeted procedure separately detected it in muscle. The high-resolution work described for this investigation covered blood, urine and stomach contents, rather than the same complete specimen set as targeted testing. These findings are not a controlled comparison of the two procedures’ sensitivity in muscle. Each result must retain its actual specimen and analytical workflow.
Routine quantitative femoral-blood analysis found clonazepam at 1.5 ng/mL and 7-aminoclonazepam at 140 ng/mL. These are different analytes from clonazafone. The authors cautioned that bacterial conversion of clonazepam after death and possible continued prodrug conversion could alter the pattern; clonazafone postmortem-stability data were unavailable. The measurements cannot be read as a validated clock for ingestion or concentrations at the instant of death.
What did the case establish about death?
The reported cause was combined intoxication involving fluoro-etonitazene, clonazepam and amphetamine. Pulmonary and cerebral edema were among the autopsy findings considered. That integrated conclusion should not be reduced to “clonazafone was present, therefore it alone caused death.” This single case supplied neither a clonazafone fatal-concentration threshold nor an impairment threshold.
In reviewing a similar investigation, the useful questions concern which specimens remain, which parent and metabolite targets were tested, the sensitivity of each workflow, reference-material quality and the distinction between approximate and validated quantitative results.
See also vitreous humor versus blood for screening and why a negative autopsy drug screen has a defined scope.
Primary source
Malzacher J, Pulver B, Heller N, et al. Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioid. International Journal of Legal Medicine. 2026;140:769–778. Published online October 20, 2025. doi:10.1007/s00414-025-03627-7.
Leave a Reply